Mayne Pharma Group Limited
MAYNF
$3.29
-$0.23-6.54%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -84.72% | -238.10% | -158.78% | -171.58% | -262.38% |
| Total Depreciation and Amortization | 78.99% | 92.95% | 103.58% | -3.46% | -51.82% |
| Total Amortization of Deferred Charges | 225.89% | 153.22% | 91.30% | -24.35% | -69.93% |
| Total Other Non-Cash Items | 127.10% | 138.34% | 123.15% | 118.21% | 109.64% |
| Change in Net Operating Assets | 132.29% | -126.61% | -128.38% | -130.46% | -132.15% |
| Cash from Operations | 101.20% | 82.59% | 73.95% | 64.85% | 56.95% |
| Capital Expenditure | -270.65% | -184.54% | -106.55% | 17.13% | 67.05% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -177.47% | -100.14% | -89.00% | -87.23% | -85.43% |
| Cash from Investing | -188.35% | -101.25% | -89.13% | -87.50% | -85.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 69.25% | 96.23% | 96.95% | 97.41% | 97.79% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 100.00% | 0.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 14.15% | 472.86% | 415.60% | 214.61% | 156.24% |
| Cash from Financing | 100.45% | 94.54% | 94.30% | 94.23% | 94.17% |
| Foreign Exchange rate Adjustments | 266.17% | 137.65% | 76.85% | 4.83% | -264.18% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -438.11% | -141.16% | -78.44% | -76.04% | -72.81% |